Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Prostatic Neoplasms 2Glioblastoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Gliosarcoma 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 23Radiotherapy 15Radiation 7Bevacizumab 6temsirolimus 5Sirolimus 5Radiotherapy, Conformal 5Erlotinib Hydrochloride 5Carmustine 5Carboplatin 5Radiotherapy, Intensity-Modulated 4Everolimus 4Vorinostat 3Irinotecan 3veliparib 2tipifarnib 2plerixafor 2pembrolizumab 2atezolizumab 2Surgical Procedures, Operative 2Sorafenib 2Gefitinib 2Fluorodeoxyglucose F18 2Cilengitide 2Chemotherapy, Adjuvant 2vatalanib 1vandetanib 1terameprocol 1tandutinib 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Gliosarcoma × ipatasertib × Clear all
NCT02430363 2016-02-24

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

Medical Research Council

Phase 1/2 Unknown
58 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡